Eloxx Pharmaceuticals, Inc. (ELOX): Revenue
$0
Year ended 2025-12-31
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $0 | -100.0% | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | $6.36M | n/a | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | $0 | n/a | 2026-03-17, From 2023-01-01 |
| No annual figure between 2014-06-30 and 2023-12-31. | |||
| 2014-06-30 | $182.2K | n/m | 2016-10-13, From 2013-07-01 |
| 2013-06-30 | $7.8K | -96.1% | 2015-10-09, From 2012-07-01 |
| 2012-06-30 | $200.0K | n/a | 2012-10-26, From 2011-07-01 |
| No annual figure between 2010-06-30 and 2012-06-30. | |||
| 2010-06-30 | $140.0K | n/a | 2012-10-26, From 2009-07-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | 2025-12-31 | $0 | -100.0% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $237.26M | +726.7% |
| Amgen Inc (AMGN) | 2025-12-31 | $36.75B | +10.0% |
| Repligen Corp (RGEN) | 2025-12-31 | $738.26M | +16.4% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $59.42M | +4.4% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $1.22B | -0.4% |
| Biogen Inc. (BIIB) | 2025-12-31 | $9.89B | +2.2% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $14.56M | +53.2% |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $29.44B | +2.4% |
Compare ELOX, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗